A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome

Journal of the American Academy of Dermatology

Volumn 61, Issue 1, 2009, Pages 112-116

  Gardner, Jennifer M ^a   Introcaso, Camille E ^a   Nasta, Sunita D ^a   Kim, Ellen J ^a   Vittorio, Carmela C ^a   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; VORINOSTAT;

ADULT; AGED; ANOREXIA; ARTICLE; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; DIARRHEA; ERYTHEMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; PRURITUS; SEZARY SYNDROME; SKIN BIOPSY; THROMBOCYTOPENIA; TOTAL SKIN ELECTRON THERAPY;

AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROXAMIC ACIDS; INTERFERON-GAMMA; MALE; MIDDLE AGED; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 66949164822     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.11.889     Document Type: Article

References (14)

1. Kim E.J., Hess S., Richardson S.K., Newton S., Showe L.C., Benoit B.M., et al. Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest 115 (2005) 798-812
2. Girardi M., Heald P.W., and Wilson L.D. The pathogenesis of mycosis fungoides. N Engl J Med 350 (2004) 1978-1988
3. + cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia 20 (2006) 1123-1129
4. Whittaker S.J., and Foss F.M. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 33 (2007) 146-160
5. McGinnis K.S., Ubriani R., Newton S., Junkins-Hopkins J.M., Vittorio C.C., Kim E.J., et al. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. Arch Dermatol 141 (2005) 1176-1177
6. Shapiro M., Rook A.H., Lehrer M.S., Junkins-Hopkins J.M., French L.E., and Vittorio C.C. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVA cutaneous T-cell lymphoma. J Am Acad Dermatol 47 (2002) 956-961
7. Duvic M., and Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16 (2007) 1111-1120
8. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007) 31-39
9. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007) 3109-3115
10. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74 (2007) 659-671
11. Mann B.S., Johnson J.R., He K., Sridhara R., Abraham S., Booth B.P., et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T cell lymphoma. Clin Cancer Res 13 (2007) 2318-2322
12. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13 (2007) 1282-1284
13. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
14. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 (2003) 1875-1886